



## Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments

Guest Editors:

**Prof. Dr. Michael Bohlmann**

Department of Obstetrics and  
Gynecology, St. Elisabeth  
Hospital Loerrach, 79539  
Loerrach, Germany

**Prof. Dr. Ralf D. Hofheinz**

Department of Medical Oncology,  
University Hospital Mannheim,  
68167 Mannheim, Germany

Deadline for manuscript  
submissions:

**closed (20 October 2022)**

### Message from the Guest Editors

Dear Colleagues,

The introduction of an antibody-based treatment was a major milestone in therapy in patients with solid tumors, improving outcomes such as disease-free and progression-free survival as well as overall survival. This is especially true for Her2-neu-positive patients with breast or gastric cancer, both in the (neo-) adjuvant and metastatic setting. The expression of the Her2neu antigen, however, is not limited to those distinct tumor types. In recent years, therapeutic approaches expanded from therapies with antibodies and chemotherapy to the introduction of antibody–drug conjugates (ADC). In advanced stages, tumor heterogeneity caused by both overexpression or downregulation of specific antigens as well as clonal progression may play a crucial role in the development of drug resistance. Analyzing the efficacy of targeted therapies by examining the Her2 status in liquid biopsies based on circulating tumor cells offers modalities for real-time monitoring of disease progression and therapeutic response.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)